They quote p=0.179 for the OS results so, according to my basic understanding of statistics, this can't constitute evidence that sorafenib is superior. All other quoted results favour SIRT and are statistically significant. Look at the side-effect/quality of life result (p=0.005)! To me, this shows that SIRT is by far the better treatment. IMHO (Not a statistician or medico).
- Forums
- ASX - By Stock
- SRX
- Ann: Trading Halt
Ann: Trading Halt, page-38
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SRX (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
Previous Video
Next Video
SPONSORED BY The Market Online